GlassScriptPhysician profile
William S Bohlke
NPI 1225141997
$8,123.58
in general payments reported to CMS, 2019-2025
41 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $1,013 · 2021: $1,477 · 2022: $1,411 · 2023: $1,003 · 2024: $1,106 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,189.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,389.71 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,102.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $692.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $670.58 | 2021-2025 | Vraylar |
| Amgen INC. | $528.84 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $527.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $315.38 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.99 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $218.17 | 2020-2024 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $214.92 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $181.00 | 2021 | |
| Allergan, INC. | $176.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $158.90 | 2020-2024 | Takhzyro |
| E.R. Squibb & Sons, L.L.C. | $145.10 | 2019-2023 | Eliquis |
| Glaxosmithkline, LLC. | $136.27 | 2019-2024 | Shingrix, Arexvy |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bohlke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.